Tag Archives: Cancer Immunotherapy

Coley’s Toxin – the First Immunotherapy?

Coley's Toxin - the First Immunotherapy?
Coley’s Toxin – the First Immunotherapy?

When it comes to cancer treatment, immunotherapy is a hot buzzword right now, but it may not be as new as it seems. Many scientists believe that the first immunotherapy treatments date back to the late 1800s.

Coley’s Toxins: The Original Immunotherapy?

William Coley, a surgeon in turn-of-the-century New York, made a peculiar discovery about one of his patients. Fred Stein, who had been diagnosed with cancer, began making a recovery after contracting a serious infection.

Dr. Coley thought that perhaps bacteria from the infection jump-started Stein’s immune system, causing it to attack the tumors. This experience inspired the doctor to begin treating inoperable cancer patients with bacterial injections that came to be known as Coley’s toxins.

While Coley’s treatments did achieve some success, there was little documentation to support his findings. As a result, the doctor’s peers continued to favor radiation and chemotherapy as cancer treatments of choice.

A Man Ahead of His Time

For all intents and purposes, Dr. Coley’s methods died with him in 1936. Now, more than 80 years later, immunotherapy cancer treatment is “here to stay,” according to Jill O’Donnell-Tormey, chief executive of the Cancer Research Institute.

Immunotherapies known as checkpoint inhibitors are some of the top-selling drugs around the world. Checkpoint inhibitors follow Dr. Coley’s principle of boosting the body’s own immune response.

Dr. Josef M. Issels: A Pioneer of Immunotherapy

We’re proud to carry on the legacy of our founder, Dr. Josef M. Issels, who was also an early proponent of immunotherapy cancer treatment. Contact Issels® for more information about our individually created immunotherapy programs.

UCLA Research Shows Chimeric Antigen Receptors May Boost Immune System Response to Fight Cancer

UCLA Research Shows Chimeric Antigen Receptors May Boost Immune System Response to Fight Cancer
UCLA Research Shows Chimeric Antigen Receptors May Boost Immune System Response to Fight Cancer

Tumors have a number of ways to avoid detection and attack by the body’s immune system, making them difficult to eliminate. In a victory for cancer immunotherapy, scientists have created a synthetic protein with the ability to reverse these defenses.

Overcoming Safeguards of Tumor Cells

Most diseased cells carry proteins called antigens that trigger a response from T cells in the immune system, resulting in neutralization of the threat. In contrast, tumor cells secrete immunosuppressive cytokines, and these soluble proteins disable the immune response from T cells.

Chimeric antigen receptor (CAR) T-cell therapy, which received FDA approval in 2017, has been successfully used to treat blood cancers such as leukemia. Unfortunately, these therapies have not had a similar effect on solid tumors.

Making Cancer Work Against Itself

Building on the principle of CARs and their power to counteract the defenses of cancer cells, a team of scientists at UCLA engineered CARs to respond to soluble proteins along with surface-bound antigens. In effect, cancer’s primary weapon ends up acting as an instrument of its own destruction.

Since these CARs are engineered, it opens up the possibility of using this method to create cancer immunotherapy treatments for other applications. The UCLA team has already engineered CARs that respond to various soluble proteins, including transforming growth factor (TGF) beta.

Cancer Immunotherapy: Boosting the Body’s Own Immune System

Our individually developed immunotherapy programs focus on restoring the body’s immune system and its natural defense mechanisms. These programs are non-toxic, without the adverse side effects that often accompany chemotherapy and other traditional cancer treatments.

Visit our website for more information.

An Immunotherapy and Ovarian Cancer Success Story

An Immunotherapy and Ovarian Cancer Success Story
An Immunotherapy and Ovarian Cancer Success Story

What happens when a patient responds to cancer immunotherapy that, according to advanced medical knowledge, shouldn’t work? Scientists are studying four recent cases where cancer treatment “broke the rules.”

Exceptions to the Rule?

Four women in different countries, who knew each other only through an online support group, were diagnosed with the same rare form of ovarian cancer. Each one persuaded her doctor to use immunotherapy drugs, despite conventional wisdom that the treatment was useless against ovarian cancer.

Against all odds, the patients responded positively, with their tumors going into remission and the women returning to their normal lives. Researchers are hoping to gain insight that will help develop cancer immunotherapy treatments with a broader range of applications.

Why Doctors Were Caught by Surprise

Tumor cells have an ability to deflect attacks from the body’s immune system, allowing them to multiply freely. Immunotherapy is a way of helping the immune system identify and kill cancer cells.

So far immunotherapy has been successful primarily with lung cancer, melanoma and forms with many genetic mutations. By contrast, hypercalcemic ovarian cancer, which is the form that affected the four women, is driven by a single mutation.

The theory is that a lower number of mutations “tricks” the immune system into disregarding the threat posed by cancer cells. Based on the positive results in the women with ovarian cancer, scientists at Johns Hopkins and M.D. Anderson Cancer Center are conducting trials with the aim of further refining cancer immunotherapy.

Comprehensive Cancer Immunotherapy Treatments at Issels®

Our individually created immunotherapy programs are often successful where other conventional treatments have failed. Contact us for more information.

New Swedish Study Shows Selenium-containing Enzyme May Combat Cancer

New Swedish Study Shows Selenium-containing Enzyme May Combat Cancer
New Swedish Study Shows Selenium-containing Enzyme May Combat Cancer

One of the challenges of cancer treatment research is distinguishing between effects on healthy cells and tumor cells. Scientists in Sweden have been focusing on inhibiting a chemical that is beneficial to human health but also promotes the growth of cancer.

The Connection Between Selenium Intake and Cancer

Selenium is a chemical element with a Recommended Dietary Allowance determined by the Food and Drug Administration. An enzyme known as TrxR1 contains selenium, which supports cell growth and protects them from oxidative stress. Raised levels of TrxR1 are also associated with occurrences of cancer, although the causes are not yet understood.

While TrxR1 inhibitors are available, a research team at Karolinska Institutet in Sweden analyzed nearly 400,000 molecules looking for new and more specific versions. Their search turned up three molecules, which the scientists used to treat more than 60 types of cancer cells under laboratory conditions.

Treating Cancer While Sparing Healthy Cells

Healthy cells proved to be far less vulnerable to the TrxR1 inhibitors. Team leader Professor Elias Arner explained that the difference may be caused by cancer cells having a greater vulnerability to oxidative stress than normal cells.

Cisplatin, melfalan and some of the other cancer drugs currently in use contain TrxR1 inhibitors, although not the ones that were the focus of this study. It’s unclear whether the TrxR1 inhibition factor plays a role in the effectiveness of the drugs, but researchers will continue investigating these new molecules as cancer treatments.

Cancer Treatment Designed for Your Needs

Issels® has a successful history of creating individual cancer treatment programs addressing a patient’s particular needs. Contact us for more information.

Immunotherapy is Changing Cancer Treatment Again in Exciting New Ways

Immunotherapy is Changing Cancer Treatment Again in Exciting New Ways
Immunotherapy is Changing Cancer Treatment Again in Exciting New Ways

If you think you’ve been hearing the term “immunotherapy” a lot lately, it’s not your imagination. Scientists consider this growing form of cancer treatment to be a game-changer on a par with the polio vaccine and organ transplants.

Researchers Commit to Immunotherapy

The University of Pittsburgh Medical Center, one of the top-rated health enterprises in the U.S., recently demonstrated their major commitment to immunotherapy research. Earlier this year, they announced plans for a $200 million Immune and Transplant Therapy facility to open in 2020.

UPMC’s newest center will focus on researching treatments to disrupt cancer growth as well as reduce the need for immune-suppressing drugs with transplant patients. Dr. Robert Ferris, director of UPMC’s Hillman Cancer Center, referred to the facility as “swinging for the fences.”

How Immunotherapy Works

Immunotherapy cancer treatments fall into one of two categories:

Checkpoint modulator drugs trigger the body’s own immune cells to attack and destroy cancer cells.

– Cell therapies, such as the recently approved CAR-T therapy, involve harvesting a patient’s T-cells and programming them to fight cancer cells, at which point they are reinfused back into the patient’s system.

Dr. Sandip Patel of the University of California San Diego called immunotherapy a “paradigm shift” in cancer treatment. According to Patel, when immunotherapy is effective, it can lead to a patient’s cancer going into remission for years.

Issels®: A Pioneer in Immunotherapy Cancer Treatments

Our founder, Dr. Josef M. Issels, predicted the rise of immunotherapy more than 20 years ago. Visit our website to learn more about Issels® and our innovative approach to non-toxic, individually created cancer treatment programs.

Huntington’s Disease Produced Molecules Are Fatal to Cancer Cells

Huntington's Disease Produced Molecules Are Fatal to Cancer Cells
Huntington’s Disease Produced Molecules Are Fatal to Cancer Cells

Could a clue to more effective cancer treatment be found in the biochemistry of another illness? Scientists are hopeful that the gene behind Huntington’s disease could be fatal to cancer cells without harming healthy ones.

What Is Huntington’s Disease?

Huntington’s disease is a genetically inherited condition that destroys nerve cells in the brain. There is currently treatment but no cure for the disorder, which causes a slowly progressive decline in both cognitive and physical abilities.

The faulty gene that triggers Huntington’s disease contains an excessive number of repeats of a certain sequence of nucleotides, which form the building blocks of DNA and RNA. These sequences create small interfering RNAs, which are molecules that attack specific genes crucial for cell survival.

“Assassin Molecules”

Brain cells in particular are vulnerable to the cell death caused by small interfering RNAs. Cancer cells are also highly susceptible, which is thought to be the reason why Huntington’s disease patients have such a low incidence of cancer.

A research team at Northwestern University tested these so-called “assassin molecules” on human and mouse cancer cells, including brain, breast, colon and ovarian, that were grown in a laboratory. The small interfering RNAs killed all cancer cells from both humans and mice.

Researchers were encouraged that the treatment also showed no toxicity to healthy cells. Further testing is underway to find a more targeted form of delivery.

Targeted Cancer Treatment at Issels®

Our individually developed, non-toxic immunotherapy programs focus on destroying cancer cells and their environment while sparing healthy tissues. Contact us for more information about cancer vaccines and other targeted cancer treatment protocols at Issels®.